Useful Resources
We’re passionate about supporting your success when it comes to diagnosing and treating canine osteoarthritis (OA). With the materials and tools on this page, you’ll have the important resources you need to provide your patients with high-quality care.
Care from Day 1
Supporting your canine OA patients begins with understanding, assessing and treating their condition from the moment it starts.
*Approved for use in dogs older than 9 months of age and greater than 8 pounds.
Monitoring is recommended if used long-term.
Screen from a young age
Treat all stages of OA from earliest clinical signs*
Prescribe Galliprant® (grapiprant tablets) for safe and effective pain relief
Resources for Veterinarians
Use the resources below to help you provide the highest quality of care and identify canine OA from earliest clinical signs.
Interactive COAST Tool
COAST is an innovative canine OA staging tool designed by a consortium of international experts in veterinary surgery and pain management. With COAST, you can start the conversation about canine OA with pet owners before it sets in, and monitor OA over time.
A Case of Inspiration
Feel inspired by the stories of veterinarians preserving joy in the lives of their patients and their families.
Orthopedic Health Assistant (OHA) Tool
Improve your orthopedic examinations with our step-by-step videos, expert-led demonstrations, and supporting materials and resources.
Indication
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Important Safety Information
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.
© 2022 Elanco or its affiliates. Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
PM-US-19-1929(2)